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Prosthesis–Patient Mismatch
in the Transcatheter Aortic
Valve Replacement Era*
E. Murat Tuzcu, MD, Alper Özkan, MD,
Samir R. Kapadia, MD
Cleveland, Ohio
In an insightful report in 1978, Rahimtoola (1) pointed to
the fact that “mismatch can be considered to be present
when the effective prosthetic valve area, after insertion into
the patient, is less than that of a normal human valve.” He
recognized that most patients have some residual aortic
stenosis after aortic valve replacement and suggested that
moderate or severe residual aortic stenosis may have clinical
significance, although more work is needed to be done to
better understand this phenomenon and identify its clinical
implications.
See page 1910
Over the years, controversies surrounding prosthesis–
patient mismatch (PPM) have stemmed from a lack of
consensus on the definition of the problem, its clinical
implications, and potential preventive and therapeutic mea-
sures. The debate has intensified in the era of transcatheter
aortic valve replacement (TAVR). Potential inaccuracies of
annular measurement and limited transcatheter valve sizes
create new challenges in optimizing prosthesis size for
TAVR. Moreover, issues surrounding the measurement of
achieved orifice area make PPM a highly complex problem
in TAVR patients.
How to Define PPM?
Definitions revolve around some measure of valve size in
relation to patient size. Body surface area has been consis-
tently used to index valve size. One argument is to use the
in vitro measurements of geometric orifice area (GOA)
reported by manufacturers for each size and type of pros-
thesis (2,3). This is a more consistent value, although
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paper to disclose.whether or not it represents in vivo conditions accurately is
debatable. In the recently published American Society of
Echocardiography guidelines for evaluation of the pros-
thetic valves, the use of effective orifice area (EOA) was
recommended (4). EOA is calculated in a way similar to
native aortic valve area using the continuity equation and
left ventricular (LV) outflow diameter, assuming a circular
shape of LV outflow. These guidelines classified PPM as
hemodynamically insignificant for indexed EOA 0.85
cm2/m2, moderate for 0.65 to 0.85 cm2/m2, and severe for
0.65 cm2/m2. These cutoff values are arbitrary, which is
evidenced by the use of several different values by various
investigators (5). Irrespective of the cutoff value, the accu-
rate measurement of EOA is critical in diagnosing PPM.
Accordingly, common pitfalls in measurement, such as
contamination with the mitral regurgitation signal and
erroneous correction for malalignment of the Doppler
beam, should be avoided. High flow states and the pressure
recovery phenomenon are other potential sources of EOA
overestimation that should be kept in mind (6).
Clinical Impact of PPM
The prevalence of mild to moderate and severe PPM range
between 20% and 70% and between 2% and 11%, respec-
tively. Wide variability is due to the differing definitions of
PPM. The impact of PPM on clinical outcomes has been
studied in several retrospective studies, also using variable
definitions. The inconsistency of results was apparent in
studies investigating the clinical impact of PPM as well.
Several studies have reported increased short- (7–9) and
long-term (7) mortality, deterioration in hemodynamic
variables (9,10), reduced exercise tolerance (11), higher
postoperative New York Heart Association functional class
(9,11,12), and limited or no regression of LV hypertrophy
or mass (12–15). However, a number of investigations have
reported similar survival, New York Heart Association
functional class, and LV mass index for those with and
without PPM (2,3,16,17). Several explanations have been
proposed to explain these inconsistencies. Differences in
definitions depending on the use of GOA or EOA are one,
whereby the clinical impact is more commonly seen in
studies using EOA compared with GOA. Other possible
reasons for the discrepancy include differences in the studied
severity of PPM, confounding effects of age, sex, and other
comorbidities, possible treatment biases at different centers,
and the retrospective nature of all studies, most of which
had relatively small sample sizes.
PPM might be an important determinant of persistent
diastolic dysfunction with incomplete regression of LV
hypertrophy (18). In contrast, comorbid conditions such as
hypertension, older age, and coronary artery disease are
associated with decreased systemic vascular resistance and
increased global afterload, which may diminish the possible
benefits of intervention. Assessment of valvuloarterial im-
pedance along with LV global longitudinal strain and strain
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Prosthesis–Patient Mismatch in TAVR October 25, 2011:1919–22rate analysis may help clinicians better understand the
hemodynamic impact of PPM and predict the outcomes of
TAVR and LV reverse remodeling. Because LV ejection
fraction is not a sensitive marker to detect the early recovery
of LV systolic function after TAVR, LV global strain might
be used as a more reliable method to understand changes in
LV unloading pattern.
PPM in the TAVR Era
Transcatheter valves are deployed in diseased aortic valves
without removal of the native valve. Furthermore, the
placement of these valves is at variable height in relation to
the annulus, because of deployment variability. Limited
prosthesis sizes are available, requiring use of the same-size
device for a relatively wide range of annular sizes (e.g., the
23-mm Edwards SAPIEN valve [Edwards Lifesciences,
Irvine, California] for 17- to 21-mm annuli and the 26-mm
valve for 22- to 25-mm annuli). These factors make the
assessment and prevention of PPM even more challenging.
In this issue of the Journal, Ewe et al. (19) present a
etrospective study of patients undergoing TAVR with
alloon-expandable Edwards SAPIEN valves. PPM was
efined to be present when EOA was 0.85 cm2/m2 and
as present in 18% of the investigators’ population. They
ound that LV mass reduction, left atrial size reduction, and
ormalization of filling pressure were less pronounced in
atients with PPM compared with those without. This
ranslated to diminished reductions in symptoms, as
videnced by larger proportions of patients with no
hanges in New York Heart Association functional class
mong those with PPM.
This study is one of several focusing on PPM in patients
ndergoing TAVR (20–22). In these studies, moderate
PM (0.60 to 0.85 cm2/m2) was encountered in about 20%
and severe PPM (0.60 cm2/m2) in about 10% of patients
ndergoing TAVR. In the present study, Ewe et al. (19)
ere not able to characterize the impact of severe or
oderate PPM on outcomes, because of a relatively small
ample size. For the same reason, the impact of PPM was
ssessed only in a univariate analysis. Important procedural
ariables other than PPM could have accounted for differ-
nces in outcomes, but it is difficult to decipher from this
eport. It appears that most of these patients had Edwards
alloon-expandable valves, but it is not clear how many of
hese patients had SAPIEN XT valves. Although not
tatistically significant, the use of smaller valve sizes and the
ransfemoral approach were more frequently seen in patients
ith PPM. Echocardiographic follow-up was carried out at
months. It is not clear if the differences in LV dimensions
nd hemodynamic parameters would decrease or increase
ith longer follow-up. Variability in the management of
ypertension after valve replacement and the use of different
edications may have contributed to the differences in
emodynamic outcomes at follow-up, but these data are not
vailable in the present report. Furthermore, measurements oere made without the help of an independent core labo-
atory, and analysis was done retrospectively, which may be
source of bias.
The methodology of measurement of EOA in this study
eeds critical evaluation. The calculation of EOA using the
ontinuity equation requires the measurement of 3 variables:
he LV outflow tract diameter, the LV outflow tract, and
ransprosthetic flow velocities. In previous studies, 2 meth-
ds have been used to estimate the EOAs of TAVR
rostheses: some investigators have used the LV outflow
ract diameter measured at the base of the prosthetic valve
eaflets, whereas others used the diameter measured just
roximal to the prosthesis stent (20–22). In the present
tudy, the second method was used, which appears to be
ore reliable and reproducible and correlates better with
radient across the implanted transcatheter aortic valve.
This study does not focus on factors that contributed to
PM. Whether the choice of valve size, patient size, annular
ize, pre-existing calcification of the aortic valve apparatus,
r some procedural variable such as pre- or post-dilation
alloon size or positioning of the valve or measured annular
ize contributed to the development of PPM is unclear.
onsequently, it is difficult to understand how the proce-
ure can be modified to minimize PPM.
Over the years, surgical valves have seen multiple altera-
ions and innovations to improve EOA. Transcatheter
alves are also building on the same experience not only to
mprove EOA but also to potentially improve durability. It
s important to recognize that the currently available trans-
atheter valves provide better EOA compared with surgical
alves, because leaflets of these valves are mounted directly
n the stents, without a sewing ring (Fig. 1). Larger EOA
s necessary because the annulus is not prepared by excising
alcium, as is done in surgery. Balloon-expandable and
elf-expanding valves have very similar GOAs in currently
sed valves. CoreValve (Medtronic Inc., Minneapolis, Min-
esota) leaflets are mounted in the supra-annular portion of
he stent to allow for larger EOA. Edwards valves are
ounted to the stent, without compromising any space
ithin the lumen. How these different valve designs of
ranscatheter valves will affect durability is another question
ith no meaningful clinical data at this time.
Finally, the clinical significance of PPM remains unclear
n this patient population. Patients undergoing TAVR are
igh-risk patients who are typically in their 80s. It remains
o be seen whether PPM equivalent to moderate nonpro-
ressive aortic stenosis leads to any adverse outcomes in this
atient population. At least on short-term follow-up as
eported in the present study, there was no increase in
linical adverse events. Long-term outcomes will be deter-
ined foremost by valve durability and patient comorbidi-
ies. How PPM fits in this equation is unclear. However,
ess than optimal improvement in symptom relief associated
ith PPM is a concern and should be further investigated.
ptimizing the size of the aortic annulus and the availabilityf more valve sizes will help in the prevention of PPM.
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October 25, 2011:1919–22 Prosthesis–Patient Mismatch in TAVRAlthough bigger is better, knowing how much bigger is
possible without compromising the safety of TAVR is
critically important.
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